Fortress Biotech (FBIO) to Release Earnings on Tuesday

Key Points

• Fortress Biotech (FBIO) is set to release its Q2 2025 earnings on August 12th, with analysts predicting a loss of ($0.31) per share and revenue of $14.53 million.
• The stock price for Fortress Biotech currently stands at $1.90, with a market capitalization of $56.04 million and a PE ratio of -0.85.
• Fortress Biotech specializes in developing and marketing dermatology and pharmaceutical products in the United States, including treatments for acne and hyperhidrosis.

Fortress Biotech (NASDAQ:FBIO - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Fortress Biotech to post earnings of ($0.31) per share and revenue of $14.53 million for the quarter.

Fortress Biotech Stock Down 1.1%

Shares of Fortress Biotech stock traded down $0.02 on Thursday, hitting $1.86. 33,024 shares of the company traded hands, compared to its average volume of 264,030. The company has a market cap of $55.00 million, a PE ratio of -0.83 and a beta of 1.76. The company has a quick ratio of 1.55, a current ratio of 1.72 and a debt-to-equity ratio of 1.74. Fortress Biotech has a 12-month low of $1.33 and a 12-month high of $2.36. The company has a 50-day moving average price of $1.90 and a 200 day moving average price of $1.75.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.